Machaon Diagnostics is a preferred laboratory partner to pharmaceutical firms conducting clinical trials in the areas of thrombosis, hemostasis, nephology and rare disease. We offer both CAP/CLIA and GLP testing and regulatory-compliant method validation solutions for submission to the FDA and other regulatory bodies. Machaon Diagnostics has emerged as a leading laboratory for complement gene sequencing and other testing, due to our rapid turnaround and expedited study capabilities. Machaon was founded in 2003.
At Bioverativ, we are dedicated to transforming the lives of people with hemophilia, cold agglutinin disease and other rare blood disorders. As an independent biopharmaceutical company spun out of Biogen’s hemophilia business, we bring a strong legacy of innovation, world-class science, and commitment to the rare blood disorders community. We are united by a singular purpose: to create progress where patients need it most.
Kypha is a clinical diagnostic company driven by the need for reliable and accessible diagnostic testing for immune system activation, particularly surrounding the complement system. Since its founding in 2010, Kypha’s comprehensive complement activation diagnostics program has focused on sample workflows in various clinical settings in order to reduce sample management requirements and preanalytical variability. [Read More]
Quidel’s Specialty Products Group is focused on providing innovative research and diagnostic tools for identification of novel markers in autoimmune and Complement. Many of these products are unique in nature and provide researchers and clinicians valuable scientific and diagnostic information. Quidel offers products to meet biosafety testing and Complement dependent cytotoxicity testing requirements, such as normal human sera, proteins, monoclonal and polyclonal antibodies, depleted sera and Complement fragment ELISA assays.